Popular Trials
Dupilumab and Milk OIT for Cow's Milk Allergy
This trial tests if using dupilumab with milk oral immunotherapy (OIT) can help people aged 4 to 50 who are allergic to cow's milk. Dupilumab reduces allergic reactions, and OIT helps the body get used to milk. The goal is to see if this combination makes it safer and more effective for these individuals to consume milk. Dupilumab has been approved for treating certain skin conditions and has shown promise in other allergic conditions.
Behavioral Intervention
Food Allergy Mastery Program for Food Allergies
This trial will examine a new program to help teens with food allergies learn how to manage their condition, with education, problem-solving, communication, and peer support.
Beta-lactam Antibiotic
Amoxicillin for Penicillin Allergy
This trial aims to determine if patients with a reported penicillin allergy can safely receive penicillin or its derivatives. Patients will be asked specific questions to determine their risk of an allergic reaction. Low
Immunotherapy
Peanut SLIT-Tablet for Peanut Allergy
This trial tests a tablet containing small amounts of peanut protein taken under the tongue. It aims to help people with peanut allergies become less sensitive to peanuts. Participants will take gradually increasing doses to see if their tolerance improves.
Popular Filters
Trials for Food Allergy Patients
Behavioural Intervention
iREACH CDS Tool for Preventing Peanut Allergy
This trial will assess whether an electronic health record-based tool can help doctors better adhere to guidelines around preventing peanut allergies, with the goal of reducing the incidence of peanut allergies.
VR Therapy for Pain and Anxiety During Medical Procedures
This trial tests if VR can reduce pain and anxiety in children aged 7-21 during medical procedures by distracting them with a virtual world. The study compares the effectiveness of using VR versus not using VR. Virtual reality (VR) has been shown to decrease pain and anxiety in children undergoing various medical procedures.
Immunotherapy
Low-Dose Multi-Oral Immunotherapy for Food Allergies
This trial tests if giving nut-allergic children very small amounts of multiple nuts can help them tolerate these nuts without allergic reactions. The goal is to make their immune system get used to the nuts over time.
Trials for Peanut Allergy Patients
Behavioural Intervention
iREACH CDS Tool for Preventing Peanut Allergy
This trial will assess whether an electronic health record-based tool can help doctors better adhere to guidelines around preventing peanut allergies, with the goal of reducing the incidence of peanut allergies.
VR Therapy for Pain and Anxiety During Medical Procedures
This trial tests if VR can reduce pain and anxiety in children aged 7-21 during medical procedures by distracting them with a virtual world. The study compares the effectiveness of using VR versus not using VR. Virtual reality (VR) has been shown to decrease pain and anxiety in children undergoing various medical procedures.
Immunotherapy
Oral Immunotherapy for Peanut Allergy
This trial studies how gradually eating small amounts of peanut can help people with peanut allergies reduce their allergic reactions. It focuses on individuals aged 6 months to 65 years and aims to improve their quality of life and predict who will benefit most from this treatment. A specific preparation of peanut allergen was approved for younger patients with a peanut allergy.
Microbiome Modulator
VE416 for Peanut Allergy
This trial tests VE416, a capsule with friendly bacteria, combined with an antibiotic and peanut flour, to help people with peanut allergies. The bacteria activate in the intestines and may help prevent allergic reactions. The goal is to see if this combination is safe and effective.
Phase 3 Trials
Long-term Ligelizumab for Food Allergy
This trial is testing the long-term safety and effectiveness of ligelizumab, a medication for food allergies. Ligelizumab is a new type of medication that has shown promise in treating certain allergic conditions and is now being tested for food allergies. It works by blocking proteins that trigger allergic reactions, helping to prevent symptoms. It is being tested on people who have already participated in an earlier study of this medication.
Trials With No Placebo
Behavioural Intervention
iREACH CDS Tool for Preventing Peanut Allergy
This trial will assess whether an electronic health record-based tool can help doctors better adhere to guidelines around preventing peanut allergies, with the goal of reducing the incidence of peanut allergies.
VR Therapy for Pain and Anxiety During Medical Procedures
This trial tests if VR can reduce pain and anxiety in children aged 7-21 during medical procedures by distracting them with a virtual world. The study compares the effectiveness of using VR versus not using VR. Virtual reality (VR) has been shown to decrease pain and anxiety in children undergoing various medical procedures.
Immunotherapy
Oral Immunotherapy for Peanut Allergy
This trial studies how gradually eating small amounts of peanut can help people with peanut allergies reduce their allergic reactions. It focuses on individuals aged 6 months to 65 years and aims to improve their quality of life and predict who will benefit most from this treatment. A specific preparation of peanut allergen was approved for younger patients with a peanut allergy.
Immunotherapy
Low-Dose Multi-Oral Immunotherapy for Food Allergies
This trial tests if giving nut-allergic children very small amounts of multiple nuts can help them tolerate these nuts without allergic reactions. The goal is to make their immune system get used to the nuts over time.
Barrier Cream
Skin Barrier Cream + Fluticasone Propionate for Eczema
This trial is testing whether using a special moisturizing cream and a mild steroid cream can help infants with early signs of eczema. The goal is to see if this treatment can reduce eczema severity and prevent food allergies. The study focuses on very young babies who have dry skin or early eczema symptoms. EpiCeramâ„¢ has been previously tested for preventing eczema in infants with a family history of allergic disease.
View More Related Trials
Frequently Asked Questions
Introduction to allergy
What are the top hospitals conducting allergy research?
When it comes to cutting-edge clinical trials addressing allergies, several hospitals are at the forefront of innovation. Massachusetts General Hospital in Boston is currently conducting four active allergy trials and made history by recording their first trial in this field just last year, in 2021. In New york City, the Icahn School of Medicine at Mount Sinai is also actively engaged with four ongoing allergy trials. Although they have yet to record any completed trials specifically for allergies, their expertise and dedication make them a vital player in the field.
Meanwhile, Western Sky Medical Research located in El Paso has three active allergy trials underway and an impressive track record of ten previously conducted investigations since their inaugural allergy trial debuted back in 2007. On the other hand, Novartis Investigative Sites both in Louisville and Baltimore may not have any recorded past or completed allergy trials but are currently contributing with two active studies each.
These top hospitals represent beacons of hope for individuals dealing with allergies across the country. With research efforts focused on understanding allergic reactions better and developing new treatments, these institutions play a crucial role in improving lives affected by this widespread condition. By pushing boundaries through innovative clinical trials, they aim to bring relief and advancements that will enhance our overall quality of life amidst allergen-filled environments that challenge us daily
Which are the best cities for allergy clinical trials?
Chicago, Illinois; Boston, Massachusetts; and New york, New York emerge as the top cities for allergy clinical trials. In Chicago, there are 20 ongoing trials investigating treatments like iREACH CDS Tool, Prebiotic, and Tri-lipid skin barrier cream (Epiceram). Boston follows closely with 8 active trials focusing on Peanut SLIT-tablet, Ligelizumab 120 mg, and Segmental allergen challenge. Meanwhile, New York hosts 7 studies examining DBV1605 and Ligelizumab 120 mg among others. These cities provide individuals with allergies access to cutting-edge research and potential breakthroughs in treatment options.
Which are the top treatments for allergy being explored in clinical trials?
Allergy research is a field of ongoing exploration, with several promising treatments currently being studied in clinical trials. Leading the pack are sublingual immunotherapy (SLIT) and oral immunotherapy (OIT), both showing potential to revolutionize allergy treatment. SLIT involves placing allergen extracts under the tongue to desensitize the immune system, while OIT focuses on gradually increasing exposure to allergens through controlled ingestion. These innovative approaches offer hope for improved management and long-term relief for individuals suffering from allergies.
What are the most recent clinical trials for allergy?
Exciting advancements in allergy research have led to the emergence of several recent clinical trials. Ligelizumab, a medication being evaluated in Phase 3 trials at a dose of 120 mg, shows promise as a potential treatment for allergies. Another trial focuses on remibrutinib, which is undergoing Phase 2 testing at low doses with encouraging results. Additionally, researchers are exploring the effectiveness of oral challenges and peanut SLIT-tablets to better understand and manage allergies. In another study, investigators are evaluating Abrocitinib at a dosage of 100mg for its potential impact on allergic reactions. These clinical trials offer hope for improved treatments that can enhance the quality of life for individuals affected by allergies.
What allergy clinical trials were recently completed?
A noteworthy clinical trial has recently concluded, shedding light on advancements in the field of allergy treatment. In December 2020, MEDA Pharma GmbH & Co. KG successfully completed a trial for Treatment A (Dymista), which is a fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 5. This significant milestone highlights ongoing efforts to enhance therapies for allergies and offers hope to individuals who suffer from these conditions.